Global Alzheimer’s Disease Clinical Trial Pipeline Highlights, 2019 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Alzheimer’s Disease Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.

Alzheimer’s Disease Pipeline Highlights – 2019, provides most up-to-date
information on key pipeline products in the global Alzheimer’s Disease
market. It covers emerging therapies for Alzheimer’s Disease in active
clinical development stages including early and late stage clinical
trials. The pipeline data presented in this report helps executives in
tracking competition, identifying partners, evaluating opportunities,
formulating business development strategies, and executing in-licensing
and out-licensing deals.

Clinical Trial Stages:

The report provides Alzheimer’s Disease pipeline products by clinical
trial stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Alzheimer’s Disease pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Alzheimer’s Disease pipeline products by the company.

Short-term Launch Highlights:

Find out which Alzheimer’s Disease pipeline products will be launched in
the US and Ex-US to 2024.

Summary:

• Alzheimer’s Disease phase 3 clinical trial pipeline products
• Alzheimer’s Disease phase 2 clinical trial pipeline products
• Alzheimer’s Disease phase 1 clinical trial pipeline products
• Alzheimer’s Disease preclinical research pipeline products
• Alzheimer’s Disease discovery stage pipeline products
• Alzheimer’s Disease pipeline products short-term launch highlights

Key Topics Covered:

1. Alzheimer’s Disease Pipeline by Stages

2. Alzheimer’s Disease Phase 3 Clinical Trial Insights

3. Alzheimer’s Disease Phase 2 Clinical Trial Insights

4. Alzheimer’s Disease Phase 1 Clinical Trial Insights

5. Alzheimer’s Disease Preclinical Research Insights

6. Alzheimer’s Disease Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/o5b42k

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Clinical
Trials, Alzheimer’s
Disease Drugs